Lilly says further head-to-head trial data back Zepbound over Novo’s Wegovy
Eli Lilly said Sunday that new data on Zepbound show the GIP/GLP-1 dual agonist is a better weight loss drug than Novo Nordisk’s Wegovy. Almost 65% of obese or overweight people treated with Zepbound...
View ArticleTrump signs ‘most favored nation’ order to try to lower US drug prices
The White House plans to force down prices of drugs sold in the US by threatening to tie costs to rates paid by other countries, a directive that could have huge impacts but is almost ...
View ArticleFDA clears in vivo blood stem cell editing trial; Abeona's $155M PRV sale
Plus, news about CytomX, Valneva, Lenz and Lotus Pharmaceutical: 🧪 After China, US greenlights first trial of in vivo blood stem cell editing: Ensoma
View ArticleExclusive: Patrick Hsu’s startup Stylus Medicine launches, looks beyond...
Stylus Medicine, an ambitious startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes will help solve some of the biggest and most competitive ...
View ArticleRoche could rethink $50B US expansion plan if new policies 'harm' operations
Roche said its $50 billion promise to expand its manufacturing footprint in the US has the potential to be “reassessed” — the same day the Swiss pharma added further details on how it would spend part ...
View ArticleRepublican tax cut bill includes PBM, drug price negotiation changes
The latest version of a massive and wide-ranging tax cut bill includes several pro-pharma reforms related to pharmacy benefit managers and the way the drug price negotiation program deals with orphan...
View ArticleTrump's drug price plan is light on details, may have little impact
The White House's plan to realign US drug prices with similar high-income countries has ignited a wave of questions about how or even if drug companies will come to the table and work with the ...
View ArticlePharma investors brush off Trump’s ‘most favored nation’ plan as stocks rise
President Donald Trump on Monday made a sweeping promise to bring down drug prices and stop pharma companies from taking advantage of the US. Wall Street seems unfazed. As details of Trump’s
View ArticleDutch biotech Azafaros gets $146M for Phase 3 trials in three metabolic...
The last time Dutch biotech Azafaros disclosed a financing round — a €25 million Series A — the world was a few weeks away from Covid-19 lockdowns. Five years and three months later, the ...
View ArticleBayer Q1 earnings: 2,000 jobs cut as it homes in on year-end rehaul target
Bayer has been ramping up layoffs in recent months as it edges closer to its end-of-year target to complete its management reorganization that was first announced in 2023. The German conglomerate ...
View ArticleGalapagos backpedals on separation plans, CEO Paul Stoffels exits early
A month ago, former AbbVie and Neumora executive Henry Gosebruch was named the CEO of Galapagos' planned spinout, which would be handed €2.45 billion to hunt for drug candidates and build a ...
View ArticleEndpoints Livestream: Trump's 'most favored nation' plan to cut drug prices
Today on Post Hoc Live, Drew Armstrong talked with Nick Shipley, the former top lobbyist for the biotech industry, to break down President Trump's "most favored nation" executive order on drug pricing....
View ArticleTIGIT graveyard expands as GSK drops late-stage asset with iTeos
At last year's ESMO conference, there was hope that the TIGIT field still had a leg to stand on as GSK and its partner iTeos propped up their Phase 2 lung cancer ...
View ArticleUnitedHealth Group CEO Andrew Witty steps down
Andrew Witty is out as CEO of UnitedHealth Group after a tumultuous couple of years that included the shooting death of a top executive and a massive cyberattack. Witty, who the company said is...
View ArticleAxsome's $570M loan with Blackstone; Altimmune makes its own credit deal
Plus, news about Neumora, Erasca, FibroGen, Tilt Biotherapeutics, Sangamo, Leap Therapeutics, Remedy Plan, Lexeo, Karyopharm, Tango Therapeutics and Humacyte: Axsome Therapeutics gets Blackstone’s...
View ArticleCytokinetics gets an 'incremental' win for delayed heart drug
Cytokinetics’s aficamten is better than the standard of care in a heart muscle disease, the company said Tuesday. The development is positive, but with aficamten’s approval submission delayed, it will...
View ArticleArcturus to prioritize mRNA therapeutics in bid to boost rare disease programs
Arcturus Therapeutics is doubling down on mRNA technology. The biotech said Monday that it's prioritizing its experimental self-amplifying mRNA drugs, with a focus on programs for cystic fibrosis and a...
View ArticleSome generics, biosimilar drugmakers say they can withstand tariff impact
A handful of generic and biosimilar manufacturers have said they feel prepared to ride out President Donald Trump’s potential pharma-specific tariffs due to their domestic production footprints and not...
View ArticleHHS issues guidance for third round of drug price negotiations
The Trump administration laid out for the first time how Part B drugs could be selected for Medicare drug price negotiations under guidance that seeks to align with and improve transparency in the...
View Article